https://doi.org/10.4081/reumatismo.2019.1153
Infliximab in the treatment of Budd-Chiari syndrome in Behçet’s disease
Submitted: 1 May 2018
Accepted: 17 July 2019
Published: 24 October 2019
Accepted: 17 July 2019
Abstract Views: 1231
PDF: 763
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Behçet’s disease is a chronic autoinflammatory disorder that usually presents with recurrent oral and genital ulcers, uveitis, skin lesions and arthritis. Any organ, however, can be involved and in a subgroup of patients the large vascular lesions are the predominant feature (vasculo-Behçet disease). We report a case of a 27-yearold man with Behçet’s disease who developed Budd-Chiari syndrome while on immunosuppressive therapy. Infliximab resulted in a rapid and total clinical remission. Literature data have shown that antitumor necrosis factor alpha (anti-TNF-α) agents including infliximab can suppress disease activity but there is no long-term experience on tapering and/or discontinuation of treatment under clinical remission. Our case supports the use of infliximab in vasculo-Behçet patients.
How to Cite
Santos, L., Rigueira, J., & Vilas, A. (2019). Infliximab in the treatment of Budd-Chiari syndrome in Behçet’s disease. Reumatismo, 71(3), 163–165. https://doi.org/10.4081/reumatismo.2019.1153
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- A. Alunno, O. Bistoni, F. Pratesi, F. Topini, I. Puxeddu, V. Valentini, G. Cafaro, E. Bartoloni, P. Migliorini, R. Gerli, Association between anti-citrullinated alpha enolase antibodies and clinical features in a cohort of patients with rheumatoid arthritis: a pilot study , Reumatismo: Vol. 70 No. 2 (2018)
- G. Pasero, P. Marson, A short history of anti-rheumatic therapy - VI. Rheumatoid arthritis drugs , Reumatismo: Vol. 63 No. 2 (2011)
- S. Chandrashekara, A. Rajendran, A. Bai Jaganath, R. Krishnamurthy, Neutrophil-lymphocyte ratio, pain perception, and disease activity score may serve as important predictive markers for sustained remission in rheumatoid arthritis , Reumatismo: Vol. 67 No. 3 (2015)
- M. Manara, L. Arcarese, G. Bianchi, V. Corbelli, O. Epis, R. Laurenti, A. Migliore, M. Muratore, A. Roncaglione, M. Rossini, M. Savo, L. Sinigaglia, The impact on disability of initial treatment with methotrexate in patients with rheumatoid arthritis: results from the MARI study , Reumatismo: Vol. 68 No. 4 (2016)
- M. Rossini, D. Gatti, O. Viapiana, C. Caimmi, L. Idolazzi, E. Fracassi, S. Adami, Vitamin D and rheumatic diseases , Reumatismo: Vol. 66 No. 2 (2014)
- A. Lo Gullo, G. Mandraffino, C.O. Aragona, A. Molica Colella, A. Saitta, E. Imbalzano, Subcutaneous administration of tocilizumab is effective in myointimal hyperplasia remodelling in refractory Takayasu arteritis , Reumatismo: Vol. 69 No. 4 (2017)
- K.T. Koh, C.L. Teh, C.K. Cheah, G.R. Ling, M.C. Yong, H.C. Hong, S.C. Gun, Real-world experiences of folic acid supplementation (5 versus 30 mg/week) with methotrexate in rheumatoid arthritis patients: a comparison study , Reumatismo: Vol. 68 No. 2 (2016)
- F. Zare, M. Dehghan-Manshadi, A. Mirshafiey, The signal transducer and activator of transcription factors lodge in immunopathogenesis of rheumatoid arthritis , Reumatismo: Vol. 67 No. 4 (2015)
- K. Stefanantoni, I. Sciarra, M. Vasile, R. Badagliacca, R. Poscia, M. Pendolino, C. Alessandri, C.D. Vizza, G. Valesini, V. Riccieri, Elevated serum levels of macrophage migration inhibitory factor and stem cell growth factor β in patients with idiopathic and systemic sclerosis associated pulmonary arterial hypertension , Reumatismo: Vol. 66 No. 4 (2014)
- H.K. Aggarwal, D. Jain, A. Mittal, A. Rao, R.K. Yadav, P. Jain, Systemic lupus erythematosus presenting as fulminant lupus pneumonitis: a rare case report , Reumatismo: Vol. 68 No. 1 (2016)
<< < 6 7 8 9 10 11 12 13 14 15 > >>
You may also start an advanced similarity search for this article.
